Why Is Sportradar Stock Going Up?
Sportradar (NASDAQ:SRAD) should be on your radar for a stock…
Sell
43
VTRS Quote, Financials, Valuation and Earnings
Last price:
$9.1600
Seasonality move
:
4.44%
Day range:
$9.0100 - $9.3700
52-week range:
$8.7701 - $13.5500
Dividend yield:
5.25%
P/E ratio:
--
P/S ratio:
0.74x
P/B ratio:
0.59x
Volume:
71.8M
Avg. volume:
15.9M
1-year change:
-23.81%
Market cap:
$10.9B
Revenue:
$14.7B
EPS (TTM):
-$0.53
Analysts' Opinion
-
Consensus RatingViatris has received a consensus rating of Hold. The company's average rating is a Hold based on 2 Buy ratings, 5 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $11.7625, Viatris has an estimated upside of 28.55% from its current price of $9.1501.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $9.0000 representing 100% downside risk from its current price of $9.1501.
Fair Value
-
According to the consensus of 7 analysts, Viatris has 28.55% upside to fair value with a price target of $11.7625 per share.
VTRS vs. S&P 500
-
Over the past 5 trading days, Viatris has overperformed the S&P 500 by 0.04% suggesting its relative strength compared to the major market average is strong at this time.
Share Buyback
-
Viatris does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Viatris revenues have been falling on a year-over-year basis for 12 quarters in a row. In the most recent quarter Viatris reported revenues of $3.5B.
Earnings Growth
-
Viatris earnings have been falling on a year-over-year basis for 1 quarter in a row. In the most recent quarter Viatris reported earnings per share of -$0.43.
Enterprise value:
23.9B
EV / Invested capital:
0.73x
Price / LTM sales:
0.74x
EV / EBIT:
47.12x
EV / Revenue:
1.62x
PEG ratio (5yr expected):
--
EV / Free cash flow:
12.28x
Price / Operating cash flow:
5.64x
Enterprise value / EBITDA:
8.47x
Gross Profit (TTM):
$5.6B
Return On Assets:
-1.4%
Net Income Margin (TTM):
-4.3%
Return On Equity:
-3.22%
Return On Invested Capital:
-1.75%
Operating Margin:
-1.08%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2023-12-31 | 2024-12-31 | |
| Income Statement | ||||||
| Revenue | $16.3B | $15.4B | $14.7B | $3.8B | $3.5B | |
| Gross Profit | $6.5B | $6.4B | $5.6B | $1.6B | $1.2B | |
| Operating Income | $1.7B | $983.3M | $389.3M | -$212.1M | -$38.2M | |
| EBITDA | $6.4B | $3.5B | $2.8B | -$69.7M | $339.9M | |
| Diluted EPS | $1.71 | $0.04 | -$0.53 | -$0.64 | -$0.43 | |
| Period Ending | 2020-12-31 | 2021-12-31 | 2022-12-31 | 2023-12-31 | 2024-12-31 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $12.9B | $10.9B | $10.6B | $13B | $9.5B | |
| Total Assets | $61.6B | $54.8B | $50B | $47.7B | $41.5B | |
| Current Liabilities | $10.6B | $9.9B | $6.7B | $7.8B | $5.8B | |
| Total Liabilities | $38.6B | $34.4B | $28.9B | $27.2B | $22.9B | |
| Total Equity | $23B | $20.5B | $21.1B | $20.5B | $18.6B | |
| Total Debt | $25.8B | $23.1B | $19.3B | $18.1B | $14B | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2023-12-31 | 2024-12-31 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | $3B | $2.9B | $2.3B | $568.5M | $482.7M | |
| Cash From Investing | $1.5B | -$864.5M | $1.8B | $26.7M | -$168.7M | |
| Cash From Financing | -$3.9B | -$2.3B | -$4.3B | -$926.1M | -$1.4B | |
| Free Cash Flow | $2.5B | $2.3B | $1.9B | $278.5M | $329.3M | |
VTRS
Sector
Market Cap
$10.9B
$39.2M
Price % of 52-Week High
67.53%
45.93%
Dividend Yield
5.25%
0%
Shareholder Yield
11.36%
-0.81%
1-Year Price Total Return
-23.81%
-38.63%
Beta (5-Year)
0.922
0.774
Dividend yield:
5.25%
Annualized payout:
$0.48
Payout ratio:
-90.63%
Growth streak:
0 years
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Technicals
8-day SMA
Sell
Level
$9.2606
200-day SMA
Sell
Level
$11.4496
Bollinger Bands (100)
Sell
Level
10.3447 - 12.8047
Chaikin Money Flow
Buy
Level
245.6M
20-day SMA
Sell
Level
$9.7438
Relative Strength Index (RSI14)
Sell
Level
34.3761
ADX Line
Sell
Level
38.675
Williams %R
Neutral
Level
-74.5096
50-day SMA
Sell
Level
$10.6061
MACD (12, 26)
Sell
Level
-0.4325
25-day Aroon Oscillator
Sell
Level
-4
On Balance Volume
Neutral
Level
492M
Financial Scores
Sell
Altman Z-Score
(Annual)
Level (0.9628)
Sell
CA Score
(Annual)
Level (-0.6259)
Buy
Beneish M-Score
(Annual)
Level (-2.78)
Buy
Momentum Score
Level (4)
Buy
Ohlson Score
Level (-1.3403)
Buy
Piotroski F Score
(Annual)
Level (5)
Sell
Quality Ratio Score
Level (2)
Buy
Fundamental Score
Level (5)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Viatris was formed in November 2020 through the combination of Upjohn, a wholly owned subsidiary of Pfizer that specialized in off-patent drugs, and Mylan, a global pharmaceutical manufacturer that focused on generic and specialty drugs. By joining forces, Viatris became one of the largest generic drug manufacturers in the world, servicing over 165 countries. Generics (commoditized and complex) and biosimilars make up roughly 40% of Viatris' total sales. Remaining 60% of sales is derived from its portfolio of legacy products which includes Lipitor, Norvasc, Lyrica, and Viagra. While it covers more than 10 major therapeutic areas, Viatris has identified dermatology, ophthalmology, and gastroenterology as its three key areas of focus for future innovations.
Stock Forecast FAQ
In the current month, VTRS has received 2 Buy ratings 5 Hold ratings, and 0 Sell ratings. The VTRS average analyst price target in the past 3 months is $11.7625.
-
Where Will Viatris Stock Be In 1 Year?
According to analysts, the consensus estimate is that Viatris share price will rise to $11.7625 per share over the next 12 months.
-
What Do Analysts Say About Viatris?
Analysts are divided on their view about Viatris share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Viatris is a Sell and believe this share price will drop from its current level to $9.0000.
-
What Is Viatris's Price Target?
The price target for Viatris over the next 1-year time period is forecast to be $11.7625 according to 7 Wall Street analysts, 2 of them rate the stock a Buy, 0 rate the stock a Sell, and 5 analysts rate the stock a Hold.
-
Is VTRS A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Viatris is a Hold. 5 of 7 analysts rate the stock a Hold at this time.
-
How Can I Buy Shares Of VTRS?
You can purchase shares of Viatris via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, tastytrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Viatris shares.
-
What Is The Viatris Share Price Today?
Viatris was last trading at $9.1600 per share. This represents the most recent stock quote for Viatris. Yesterday, Viatris closed at $9.1501 per share.
-
How To Buy Viatris Stock Online?
In order to purchase Viatris stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is Roblox Stock a Buy, Sell or Hold?
Gaming company Roblox (NYSE:RBLX) operates a massive platform that allows…
Is Shopify a Millionaire Maker?
Shopify (NYSE:SHOP) is an eCommerce platform, business services provider and…
Stock Ideas
Buy
55
Is AAPL Stock a Buy?
Market Cap: $3.3T
P/E Ratio: 36x
Buy
53
Is MSFT Stock a Buy?
Market Cap: $2.9T
P/E Ratio: 33x
Buy
51
Is NVDA Stock a Buy?
Market Cap: $2.9T
P/E Ratio: 40x
Alerts
Sell
50
RGC alert for Mar 22
Regencell Bioscience Holdings [RGC] is up 27.82% over the past day.
Sell
36
VMI alert for Mar 22
Valmont Industries [VMI] is down 12.54% over the past day.
Buy
61
ALNY alert for Mar 22
Alnylam Pharmaceuticals [ALNY] is up 11.7% over the past day.
